Literature DB >> 16328005

Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.

Ekkehard Kunze1, Frederike Von Bonin, Carola Werner, Maike Wendt, Thilo Schlott.   

Abstract

Tumor suppressor genes play a prominent role in the modification and progression of urinary bladder carcinogenesis as a result of classic genetic alterations. Little is known about the potential significance of epigenetic events, mediated by DNA hypermethylation. This prompted our investigation to explore the global Alu methylation and the promoter methylation of the novel putative tumor suppressor genes caveolin-1 and hDAB2IP, and of p53 in transitional cell carcinomas (TCC), squamous cell carcinomas and undifferentiated small cell carcinomas of the urinary bladder. Quantitative GeneScan analysis revealed that the various histopathological tumor entities showed considerable interindividual variations in the global methylation, but the overall rate did not significantly differ between the various cancer subtypes. With methylation-specific PCR, a high frequency of methylation of the promoter region of the caveolin-1 gene was detected in undifferentiated small cell carcinomas (50%) and in squamous cell carcinomas (25.9%), while TCC were found not to be methylated. By immunohistochemistry, all squamous cell carcinomas showed a strong diffuse overexpression of caveolin-1, whereas undifferentiated small cell cancers lacked any expression. High-grade, high-stage TCC disclosed a higher incidence (60%) and a substantially stronger expression than low-grade, low-stage TCC (42.9%). Our findings suggest that hypermethylation of the caveolin-1 gene and an abnormal protein expression play a crucial role in cell differentiation, and in the phenotypical conversion of TCC into nonurothelial carcinomas. Promoter methylation of the hDAB2IP gene occurred more frequently in advanced muscle invasive (72.7%) than in superficial noninvasive (50%) TCC. DNA hypermethylation of p53 was detected in a quarter of the low-grade, low-stage TCC and undifferentiated small cell carcinomas, but only sporadically in squamous cell carcinomas, and was absent in high-grade, high-stage TCC. In conclusion, aberrant methylation and abnormal protein expression of the caveolin-1-gene is involved in the formation of nonurothelial carcinomas of the urinary bladder and promoter methylation of the hDAB2IP gene in the progression of TCC from a low to a high malignant potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16328005

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  13 in total

1.  Transcriptional repression of Caveolin-1 (CAV1) gene expression by GATA-6 in bladder smooth muscle hypertrophy in mice and human beings.

Authors:  Ettickan Boopathi; Cristiano Mendes Gomes; Robert Goldfarb; Mary John; Vittala Gopal Srinivasan; Jaber Alanzi; S Bruce Malkowicz; Hasmeena Kathuria; Stephen A Zderic; Alan J Wein; Samuel Chacko
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer.

Authors:  Shibu Thomas; Jonathan B Overdevest; Matthew D Nitz; Paul D Williams; Charles R Owens; Marta Sanchez-Carbayo; Henry F Frierson; Martin A Schwartz; Dan Theodorescu
Journal:  Cancer Res       Date:  2010-12-10       Impact factor: 12.701

3.  Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.

Authors:  Carlotta Borsoi; Fransisca Leonard; Yeonju Lee; Mohamed Zaid; Dalia Elganainy; Jenolyn Francisca Alexander; Megumi Kai; Yan Ting Liu; Yaan Kang; Xuewu Liu; Eugene J Koay; Mauro Ferrari; Biana Godin; Kenji Yokoi
Journal:  Cancer Lett       Date:  2017-07-04       Impact factor: 8.679

Review 4.  Clinical implications of caveolins in malignancy and their potential as therapeutic targets.

Authors:  Ila Tamaskar; Ming Zhou
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

5.  Electrophysiological properties of lumbosacral primary afferent neurons innervating urothelial and non-urothelial layers of mouse urinary bladder.

Authors:  Hirosato Kanda; Buffie J Clodfelder-Miller; Jianguo G Gu; Timothy J Ness; Jennifer J DeBerry
Journal:  Brain Res       Date:  2016-06-29       Impact factor: 3.252

6.  Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival.

Authors:  Yeong-Chin Jou; Yuh-Shyan Tsai; Syue-Yi Chen; Hsiao-Yen Hsieh; Hsin-Tzu Tsai; Tzong-Shin Tzai
Journal:  Virchows Arch       Date:  2016-03-22       Impact factor: 4.064

7.  The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder.

Authors:  T Qayyum; G Fyffe; M Duncan; P A McArdle; M Hilmy; C Orange; G Halbert; M Seywright; P G Horgan; M A Underwood; J Edwards
Journal:  Br J Cancer       Date:  2012-02-21       Impact factor: 7.640

8.  Hepatitis B virus X protein suppresses caveolin-1 expression in hepatocellular carcinoma by regulating DNA methylation.

Authors:  Jun Yan; Qian Lu; Jiahong Dong; Xiaowu Li; Kuansheng Ma; Lei Cai
Journal:  BMC Cancer       Date:  2012-08-15       Impact factor: 4.430

9.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

10.  Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer.

Authors:  Xianda Zhao; Yuyu He; Jun Gao; Lifang Fan; Zonghuan Li; Guifang Yang; Honglei Chen
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.